Joshua J. Meeks

This study identifies four bladder cancer subtypes using transcriptomic and genomic data, finds one subtype responsive to BCG therapy, and develops a predictive model for recurrence risk.

The paper identifies divergent macrophage-regulated T cell states in BCG responders and non-responders in high-risk bladder cancer, linking them to immune response outcomes.

This study identifies subtype-specific epigenomic and 3D genome structures in bladder cancer, linking NPAS2 to luminal subtype regulation and clinical outcomes.

The paper introduces mutSignatures, an R package for analyzing cancer mutational signatures, showing it can identify known signatures and reveal new patterns linked to clinical and molecular features.